Etelcalcetide Adverse Events: What the Label and Studies Report

Etelcalcetide is a prescription calcimimetic peptide administered intravenously in the hemodialysis setting. This page summarises what product labeling and the published literature describe about its adverse event profile. It states no verdicts about safety, gives no directions for use, and is not a substitute for a conversation with a treating clinician. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, symptom or laboratory result.

What etelcalcetide is approved to treat

In United States labeling, etelcalcetide is approved for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. The labeling states that it has not been studied in patients with chronic kidney disease who are not on hemodialysis and is not indicated for parathyroid carcinoma or primary hyperparathyroidism. Any application outside the approved indication is investigational. Decisions about whether the medicine fits a particular clinical situation sit with a prescribing clinician.

Reviews of the drug class described etelcalcetide as an agonist at the calcium-sensing receptor on parathyroid cells that lowers parathyroid hormone secretion, with downstream effects on serum calcium and phosphate (PMID 29440923). Pharmacology analyses in hemodialysis populations modelled the relationship between drug exposure and the degree of parathyroid hormone and serum calcium lowering, and researchers reported that greater exposure corresponded to greater reduction in both measures (PMID 27639083). That pharmacology explains why most of the adverse event discussion in the literature centres on calcium.

Does the label carry a boxed warning?

The United States prescribing information for etelcalcetide does not carry a boxed warning. The safety information in the label is organised under Warnings and Precautions, followed by the adverse reactions observed in the placebo-controlled and active-comparator trial programme. The sections below follow that same order: serious warnings first, then the events reported most often.

Warnings and precautions listed in the labeling

Hypocalcemia and its consequences

The labeling identifies hypocalcemia as the principal risk and notes that significant reductions in corrected serum calcium may lower the threshold for seizures, may prolong the QT interval and may contribute to ventricular arrhythmia. The label also describes symptomatic manifestations such as paresthesias, myalgias, muscle spasms and tetany, and it states that serum calcium should be measured before initiation and monitored during treatment. Published reviews of the medicine echoed this emphasis and described asymptomatic laboratory reductions in calcium as the most frequently reported finding in the trial programme (PMID 28615947).

Worsening heart failure

The label notes that in postmarketing experience, cases of worsening heart failure have been reported in patients treated with calcimimetics, and that a causal relationship to the medicine could not be excluded in all cases. Reductions in serum calcium can affect myocardial function, which is the proposed mechanism described in the labeling.

Upper gastrointestinal bleeding

The labeling records upper gastrointestinal bleeding events in clinical trials of the medicine, without an identified exact cause, and notes that patients with risk factors for upper gastrointestinal bleeding such as known gastritis, esophagitis, ulcers or severe vomiting may be at increased risk.

Adynamic bone

The label states that adynamic bone may develop if parathyroid hormone levels are chronically suppressed below approximately twice the upper limit of normal by assay, and that if parathyroid hormone falls below the recommended target range, treatment should be reassessed by the clinician. Reviews of calcimimetic therapy in dialysis populations discussed this bone turnover concern as part of the balance between parathyroid hormone suppression and skeletal health (PMID 28277829).

Hypersensitivity

The labeling describes hypersensitivity reactions, including pruritic rash, urticaria and face oedema, reported in clinical studies, and states that the product is contraindicated in patients with known serious hypersensitivity to etelcalcetide.

Common adverse reactions: what studies report

The adverse reactions section of the labeling lists blood calcium decreased, muscle spasms, diarrhea, nausea, vomiting, headache, hypocalcemia and paresthesia as the reactions reported more often with etelcalcetide than with placebo in the controlled trial programme. The randomised trial literature in hemodialysis populations reported a similar pattern. In a head to head randomised clinical trial of 683 hemodialysis patients with secondary hyperparathyroidism treated over 26 weeks, researchers reported that etelcalcetide produced greater reductions in parathyroid hormone than cinacalcet while being associated with more frequent decreases in blood calcium, and nausea and vomiting occurred in both treatment groups (PMID 28097356).

Hypocalcemia: what studies report

Calcium lowering is an extension of the intended pharmacology rather than an unrelated effect. Population pharmacokinetic and pharmacodynamic modelling in patients with chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis characterised reductions in both parathyroid hormone and corrected serum calcium as exposure dependent (PMID 27639083). In the randomised comparison with cinacalcet, the study reported that decreases in corrected serum calcium below prespecified thresholds were more common in the etelcalcetide group than in the cinacalcet group (PMID 28097356).

Longer observation produced the same theme. A one-year open-label study of intravenous etelcalcetide in hemodialysis patients with secondary hyperparathyroidism reported sustained parathyroid hormone reduction alongside reductions in serum calcium, with hypocalcemia among the adverse events recorded (PMID 30859218). A long-term Japanese cohort of hemodialysis patients treated with intravenous calcimimetic therapy likewise reported decreases in serum calcium and parathyroid hormone during follow up (PMID 28836058). Reviews comparing the two calcimimetics described more frequent laboratory hypocalcemia with the intravenous agent, often without accompanying symptoms (PMID 30009474).

Gastrointestinal events: what studies report

Nausea, vomiting and diarrhea appear in the label's adverse reaction list and in trial reports. In the randomised head to head trial in hemodialysis patients, researchers reported nausea and vomiting in both the etelcalcetide and cinacalcet groups during the 26 week comparison (PMID 28097356). Reviews discussing how the two agents differ noted that the intravenous route removes the daily oral tablet burden and has been examined in part because of oral calcimimetic gastrointestinal intolerance, while gastrointestinal events were still recorded with the intravenous agent (PMID 30009474). The upper gastrointestinal bleeding warning in the labeling is separate from these common events and is framed around patients with pre-existing risk factors.

Cardiac and neurologic signals: what studies report

The cardiac concerns described in labeling follow from calcium biology: a fall in corrected serum calcium can prolong the QT interval and, in the label's wording, may contribute to ventricular arrhythmia. Reviews of newer calcimimetics for secondary hyperparathyroidism in CKD G5D discussed electrocardiographic and cardiovascular considerations alongside the calcium lowering effect when the agents are compared (PMID 39404956). On the neurologic side, paresthesia and headache are listed label adverse reactions, and the seizure threshold caution is tied to the same hypocalcemia mechanism. Reviews of clinical utility in dialysis populations described monitoring of serum calcium as the central element of adverse event management discussed in the trial programme (PMID 28615947).

Longer-term and real-world reports: what studies report

Beyond the registration trials, a one-year study of intravenous etelcalcetide reported on both efficacy and safety across 52 weeks of treatment in hemodialysis patients, with no new category of adverse event emerging relative to the shorter controlled studies (PMID 30859218). A real-world analysis in community-based hemodialysis centres in Singapore reported on parathyroid hormone response and on calcium changes during routine care outside the trial setting (PMID 38050530). A smaller clinical report examining etelcalcetide together with paricalcitol in chronic kidney disease looked at inflammatory markers in addition to mineral parameters (PMID 36611532). Review articles covering management of hyperparathyroidism in hemodialysis summarised these data and framed hypocalcemia and gastrointestinal upset as the adverse events most often encountered (PMID 29440923).

Where the evidence is thin

• Non-dialysis chronic kidney disease. The labeling states the medicine has not been studied in patients with chronic kidney disease who are not on hemodialysis, and the trial literature summarised above enrolled hemodialysis populations (PMID 28097356).
• Pediatric use. The labeling notes that safety and effectiveness in pediatric patients have not been established.
• Pregnancy and lactation. The labeling describes limited human data and relies on animal reproductive studies for its risk summary.
• Very long-term bone outcomes. Reviews raised adynamic bone as a theoretical consequence of sustained parathyroid hormone suppression rather than a well-quantified trial endpoint (PMID 28277829).

How adverse event data are generated

1. Randomised controlled trials. Events are collected systematically and compared against placebo or an active comparator, as in the 26 week randomised comparison with cinacalcet in hemodialysis patients (PMID 28097356).
2. Open-label extension and long-term studies. These follow a single treated group over time, which shows persistence of effects but has no comparator, as in the one-year intravenous study (PMID 30859218).
3. Observational and real-world reports. These describe routine practice in defined dialysis populations and can be influenced by prescribing patterns and local protocols (PMID 38050530).
4. Postmarketing surveillance. Reports such as worsening heart failure appear in labeling without denominators, so frequency cannot be estimated from them.

Questions that belong with a prescriber

Symptoms such as tingling around the mouth, muscle cramping, twitching, seizures, fainting, black or bloody stools, persistent vomiting or new breathlessness are the kind of findings the labeling connects to its warnings, and they are matters for urgent clinical assessment rather than self-interpretation. Anyone with questions about laboratory calcium results, parathyroid hormone targets, interactions with vitamin D analogues or phosphate binders, or whether treatment should continue should talk to your prescriber. This page does not provide dosing, administration or monitoring instructions and does not evaluate whether the medicine is appropriate for any individual.

References

• Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial (JAMA, 2017)
• One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism (Nephrology Dialysis Transplantation, 2020)
• Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis (CPT: Pharmacometrics and Systems Pharmacology, 2016)
• Managing hyperparathyroidism in hemodialysis: role of etelcalcetide (International Journal of Nephrology and Renovascular Disease, 2018)
• Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide (Therapeutics and Clinical Risk Management, 2017)
• Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? (Seminars in Dialysis, 2018)
• Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore (Cureus, 2023)
• New calcimimetics for secondary hyperparathyroidism in CKD G5D: do they offer advantages? (Journal of Nephrology, 2025)
• Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation (Healthcare, 2022)
• Etelcalcetide for the treatment of secondary hyperparathyroidism (Expert Opinion on Pharmacotherapy, 2017)
• Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism (Clinical and Experimental Nephrology, 2018)